The abstract is read at the publisher; the summary is JClub's.
Updated consensus guidance for assessing treatment responses in invasive mold disease clinical trials for both adults and children was produced by an international expert panel.
- Why it matters: Existing trial endpoints rely on 2008 consensus criteria, but advances in clinical mycology and the expanding range of mold pathogens create a need to revise adjudication so outcomes reflect therapeutic response.
- What they did: An international expert panel nominated by ECMM and MSGERC convened to develop updated recommendations for defining study outcomes and evaluating treatment response in IMD trials.
- The result: The guidance, including discussion of pitfalls from discordant clinical, radiologic, and mycologic data, supports more accurate outcome assessment and highlights areas for future research.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.